Science Explorer Back to mapMap

Most cited papers from Infektionsmedizinisches Centrum Hamburg

What are the most cited papers from Infektionsmedizinisches Centrum Hamburg?

The most cited paper from Infektionsmedizinisches Centrum Hamburg is "Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022" (John Patrick Thornhill et al., 2022), with 2,219 citations. Next come "Developments in the MPI‐M Earth System Model version 1.2 (MPI‐ESM1.2) and Its Response to Increasing CO 2" (1,619) and "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study" (1,029).

Showing 50 of 60 papers. Every paper with more than 48 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 John Patrick Thornhill et al. · New England Journal of Medicine Open access 21 Jul 2022 2,219
2 Developments in the MPI‐M Earth System Model version 1.2 (MPI‐ESM1.2) and Its Response to Increasing CO 2 Thorsten Mauritsen et al. · Journal of Advances in Modeling Earth Systems Open access 13 Jan 2019 1,619
3 Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study Alison J. Rodger et al. · The Lancet Open access189 authors 2 May 2019 1,029
4 The Max Planck Institute Grand Ensemble: Enabling the Exploration of Climate System Variability Nicola Maher et al. · Journal of Advances in Modeling Earth Systems Open access 4 Jun 2019 583
5 Accuracy assessment of global barotropic ocean tide models Detlef B. Stammer et al. · Reviews of Geophysics Open access 18 Jul 2014 562
6 Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet Open access 8 Jan 2013 552
7 Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial David A. Margolis et al. · The Lancet 24 Jul 2017 509
8 International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease Frits van Rhee et al. · Blood Open access 4 Sep 2018 427
9 Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study Hans‐Jürgen Stellbrink, Chloe M. Orkin, José Ramón Arribas et al. · Clinical Infectious Diseases 9 Sep 2010 412
10 Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Paul Edward Sax, Anton Louis Pozniak, Marisa Montes et al. · The Lancet Sep 2017 406
11 The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years Mark Richard Nelson, Christine Katlama, Joan Montaner et al. · AIDS Jun 2007 353
12 Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink et al. · New England Journal of Medicine Open access 11 May 2022 329
13 Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients Christian Hoffmann, Tanya Welz, Michael Sabranski et al. · HIV Medicine 10 Nov 2016 290
14 Measuring Global Ocean Heat Content to Estimate the Earth Energy Imbalance Benoît Meyssignac et al. · Frontiers in Marine Science Open access 20 Aug 2019 266
15 HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans Christoph D. Spinner, Christoph Boesecke, Alexander Zink et al. · Infection 15 Oct 2015 248
16 COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Georg Härter, Christoph D. Spinner, Julia Roider et al. · Infection Open access 11 May 2020 245
17 Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study Frank A. Post, Graeme J Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access 27 Apr 2010 220
18 Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study Elchonon M. Berkowitz, Graeme J Moyle, Hans‐Jürgen Stellbrink et al. · The Journal of Infectious Diseases Open access 3 Nov 2014 217
19 Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia Helmut J.F. Salzer, Guido Schäfer, Martin Hoenigl et al. · Respiration 2018 201
20 Global temperature modes shed light on the Holocene temperature conundrum Jürgen Bader, Johann H. Jungclaus, N. A. Krivova et al. · Nature Communications Open access 18 Sep 2020 189
21 Skin Lesion Classification Using CNNs With Patch-Based Attention and Diagnosis-Guided Loss Weighting Nils Gessert, Thilo Sentker, Frederic Madesta et al. · IEEE Transactions on Biomedical Engineering Open access 9 May 2019 180
22 HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe Patrick Ingiliz, Thomas Martin, Alison J. Rodger et al. · Journal of Hepatology Open access 18 Sep 2016 174
23 Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV Christian Hoffmann, José L. Casado, Georg Härter et al. · HIV Medicine Open access 27 Dec 2020 166
24 Dolutegravir in antiretroviral-naive adults with HIV-1 Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin et al. · AIDS Open access 22 Mar 2013 163
25 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 Lene Ryom, AG Cotter, R De Miguel et al. · HIV Medicine Open access 3 Sep 2020 155
26 Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study Chloe M. Orkin, Enrique Bernal, Darrell H. S. Tan et al. · The Lancet HIV 16 Oct 2021 145
27 Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials Calvin J. Cohen, Jean‐Michel Molina, Isabel Cassetti et al. · AIDS 4 Dec 2012 139
28 PAIP 2019: Liver cancer segmentation challenge Yoo Jung Kim et al. · Medical Image Analysis Open access 8 Oct 2020 128
29 A High‐End Estimate of Sea Level Rise for Practitioners Roderik S. W. van de Wal et al. · Earth s Future Open access 22 Oct 2022 127
30 The Trauma Related Shame Inventory: Measuring Trauma-Related Shame Among Patients with PTSD Tuva Øktedalen, Knut Arne Hagtvet, Asle Hoffart et al. · Journal of Psychopathology and Behavioral Assessment 21 Apr 2014 124
31 Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials Kristine Mace Erlandson, Christoph C Carter, Kathleen M. Melbourne et al. · Clinical Infectious Diseases Open access 11 May 2021 121
32 Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors Christian Hoffmann, Josep Maria Llibre · Aids Reviews 18 Mar 2019 115
33 Clinical characteristics of monkeypox virus infections among men with and without HIV : A large outbreak cohort in Germany Christian Hoffmann et al. · HIV Medicine Open access 4 Sep 2022 114
34 Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada Kevin Robertson, Carmen Bayón, Jean‐Michel Molina et al. · AIDS Care Open access 16 Jul 2014 113
35 Late presentation for HIV diagnosis and care in G ermany Alexander Zoufaly, Matthias an der Heiden, U Marcus et al. · HIV Medicine 7 Nov 2011 101
36 Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial Anton Louis Pozniak, Martin H. Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases Open access 4 Jun 2014 100
37 Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk José M. Gatell, Lambert Assoumou, Graeme J Moyle et al. · AIDS Open access 6 Nov 2017 93
38 Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection Álvaro Humberto Borges, Jacqueline Neuhaus, Abdel G. Babiker et al. · Clinical Infectious Diseases Open access 8 Sep 2016 93
39 SKIM, a Candidate Satellite Mission Exploring Global Ocean Currents and Waves Fabrice Ardhuin et al. · Frontiers in Marine Science Open access 30 Apr 2019 92
40 Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease Christian Hoffmann, Holger Schmid, Markus Matthias Müller et al. · Blood 21 Jul 2011 92
41 Soil carbon sequestration simulated in CMIP6-LUMIP models: implications for climatic mitigation Akihiko Ito, Tomohiro Hajima, David M. Lawrence et al. · Environmental Research Letters Open access 10 Nov 2020 90
42 Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort Álvaro Humberto Borges et al. · Clinical Infectious Diseases Open access 16 Feb 2017 90
43 Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada Christian Hoffmann, Eva Wolf · Infection Open access 24 Oct 2020 89
44 Framework for High‐End Estimates of Sea Level Rise for Stakeholder Applications Detlef B. Stammer, Roderik S. W. van de Wal, Robert J. Nicholls et al. · Earth s Future Open access 28 Jun 2019 84
45 German‐Austrian guidelines on anal dysplasia and anal cancer in HIV‐positive individuals: prevention, diagnosis, and treatment Stefan Eßer, Alexander Kreuter, Mark Oette et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft 27 Nov 2015 69
46 Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study Graham H.R. Smith et al. · Open Forum Infectious Diseases Open access 25 Aug 2021 64
47 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study Graeme J Moyle, Hans‐Jürgen Stellbrink, Juliet Elizabeth Compston et al. · Antiviral Therapy 31 Jul 2013 61
48 Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients Josep M. Gatell, Javier O Morales‐Ramirez, Debbie P. Hagins et al. · Journal of the International AIDS Society Open access Nov 2014 60
49 Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. Giovanni Guaraldi, Manyu Prakash, Christiane Moecklinghoff et al. · PubMed Open access Apr 2015 59
50 Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus. Dominik Sebastian Nörz et al. · Journal of Clinical Virology Open access 11 Aug 2022 58

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.